logo

CABA

Cabaletta BioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CABA Profile

Cabaletta Bio, Inc.

A clinical-stage biotech company focused on targeted cell therapies for autoimmune diseases

Biological Technology
--
10/25/2019
NASDAQ Stock Exchange
164
12-31
Common stock
2929 Arch Street, Suite 600, Philadelphia, PA 19104
--
Cabaletta Bio, Inc., was incorporated under the laws of the State of Delaware in April 2017. The company is a clinical-stage biotechnology company focused on discovering and developing engineered T-cell therapies that have the potential to provide a deep and durable, perhaps therapeutic, treatment for patients with autoimmune diseases.